Supriya Lifescience Profile
Key Indicators
- Authorised Capital ₹ 35.00 Cr
as on 23-06-2024
- Paid Up Capital ₹ 16.10 Cr
as on 23-06-2024
- Company Age 16 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 122.41 Cr
as on 23-06-2024
- Satisfied Charges ₹ 121.96 Cr
as on 23-06-2024
- Revenue -12.50%
(FY 2023)
- Profit -40.81%
(FY 2023)
- Ebitda -39.77%
(FY 2023)
- Net Worth 13.61%
(FY 2023)
- Total Assets 11.64%
(FY 2023)
About Supriya Lifescience
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 543434 and on the National Stock Exchange(NSE) under SUPRIYA.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 35.00 Cr and a paid-up capital of Rs 16.10 Cr.
The company currently has active open charges totaling ₹122.41 Cr. The company has closed loans amounting to ₹121.96 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Supriya Lifescience Limited India are Krishna Raghunathan as Cfo, Rajeev Jain as Ceo, and Shweta Singh as Company Secretary. Shivani Wagh, Saloni Wagh, Balasaheb Sawant, and Seven other members serve as directors at the Company.
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Supriya Lifescience Limited offer?
Supriya Lifescience Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Antiallergic API.
Who are the key members and board of directors at Supriya Lifescience?
Executive Team (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Krishna Raghunathan | CFO | 23-Jan-2023 | Current |
| Rajeev Jain | CEO | 03-Oct-2022 | Current |
Satish Wagh  | Managing Director | 26-Mar-2008 | Current |
| Shweta Singh | Company Secretary | 26-Aug-2019 | Current |
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bhairav Chokshi | Director | 02-Feb-2015 | Current |
| Neelam Arora | Director | 25-Mar-2021 | Current |
| Kedar Karmarkar | Director | 19-Feb-2013 | Current |
| Dileep Jain | Director | 25-Mar-2021 | Current |
| Shivani Wagh | Whole-Time Director | 01-Jul-2019 | Current |
| Saloni Wagh | Whole-Time Director | 01-Jul-2019 | Current |
Financial Performance and Corporate Structure Insights of Supriya Lifescience.
Supriya Lifescience Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.5% decrease. The company also saw a substantial fall in profitability, with a 40.81% decrease in profit. The company's net worth Soared by an impressive increase of 13.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Supriya Lifescience?
In 2023, Supriya Lifescience had a promoter holding of 67.63% and a public holding of 32.38%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 May 2021 | ₹48.00 Cr | Open |
The Saraswat Cooperative Bank Ltd Creation Date: 05 Jul 2012 | ₹2.00 Cr | Open |
The Saraswat Cooperative Bank Ltd Creation Date: 27 Jun 2009 | ₹10.91 Cr | Open |
How Many Employees Work at Supriya Lifescience?
Supriya Lifescience has a workforce of 396 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Supriya Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Supriya Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
